Use of metabolomics for predicting spontaneous preterm birth in asymptomatic pregnant women: protocol for a systematic review and meta-analysis

Souza, Renato T.; Galvão, Rafael Bessa; Leite, Débora Farias Batista; Passini, Renato; Baker, Philip N.; Cecatti, José Guilherme

doi:10.1136/bmjopen-2018-026033

Cited by 5 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding spontaneous preterm birth, a still partially characterized cause of neonatal mortality and short-and long-term morbidity, metabolomics seems promising in the identification of sensible biomarkers [38].…”

Section: Metabolomics In Obstetricsmentioning

confidence: 99%

How could metabolomics change pediatric health?

Bardanzellu

Fanos

2020

Ital J Pediatr

View full text Add to dashboard Cite

In the last years, 'omics' technologies, and especially metabolomics, emerged as expanding scientific disciplines and promising technologies in the characterization of several pathophysiological processes. In detail, metabolomics, able to detect in a dynamic way the whole set of molecules of low molecular weight in cells, tissues, organs, and biological fluids, can provide a detailed phenotypic portray, representing a metabolic "snapshot." Thanks to its numerous strength points, metabolomics could become a fundamental tool in human health, allowing the exact evaluation of individual metabolic responses to pathophysiological stimuli including drugs, environmental changes, lifestyle, a great number of diseases and other epigenetics factors. Moreover, if current metabolomics data will be confirmed on larger samples, such technology could become useful in the early diagnosis of diseases, maybe even before the clinical onset, allowing a clinical monitoring of disease progression and helping in performing the best therapeutic approach, potentially predicting the therapy response and avoiding overtreatments. Moreover, the application of metabolomics in nutrition could provide significant information on the best nutrition regimen, optimal infantile growth and even in the characterization and improvement of commercial products' composition. These are only some of the fields in which metabolomics was applied, in the perspective of a precision-based, personalized care of human health. In this review, we discuss the available literature on such topic and provide some evidence regarding clinical application of metabolomics in heart diseases, auditory disturbance, nephrouropathies, adult and pediatric cancer, obstetrics, perinatal conditions like asphyxia, neonatal nutrition, neonatal sepsis and even some neuropsychiatric disorders, including autism. Our research group has been interested in metabolomics since several years, performing a wide spectrum of experimental and clinical studies, including the first metabolomics analysis of human breast milk. In the future, it is reasonable to predict that the current knowledge could be applied in daily clinical practice, and that sensible metabolomics biomarkers could be easily detected through cheap and accurate sticks, evaluating biofluids at the patient's bed, improving diagnosis, management and prognosis of sick patients and allowing a personalized medicine. A dream? May be I am a dreamer, but I am not the only one.

show abstract

Section: Metabolomics In Obstetricsmentioning

confidence: 99%

How could metabolomics change pediatric health?

Bardanzellu

Fanos

2020

Ital J Pediatr

View full text Add to dashboard Cite

show abstract

“…On the other hand, genomics represents the potential outcome, while proteomics is the phenotypical outcome [1]. Metabolomics is a promising tool for the early diagnosis of various fetal, perinatal, pediatric, and adult diseases; they may also help monitor disease progression, optimizing treatment and evaluating relevant side effects in the perspective of personalized medicine [1,[9][10][11][12][13][14][15][16][17][18]. Fetal and perinatal periods are critical phases of neonatal development.…”

Section: Introductionmentioning

confidence: 99%

Utilizing Amniotic Fluid Metabolomics to Monitor Fetal Well-Being: A Narrative Review of the Literature

Kolvatzis¹,

Tsakiridis²,

Kalogiannidis³

et al. 2023

Cureus

View full text Add to dashboard Cite

Fetal and perinatal periods are critical phases for long-term development. Early diagnosis of maternal complications is challenging due to the great complexity of these conditions. In recent years, amniotic fluid has risen in a prominent position in the latest efforts to describe and characterize prenatal development. Amniotic fluid may provide real-time information on fetal development and metabolism throughout pregnancy as substances from the placenta, fetal skin, lungs, gastric fluid, and urine are transferred between the mother and the fetus. Applying metabolomics to monitor fetal well-being, in such a context, could help in the understanding, diagnosis, and treatment of these conditions and is a promising area of research. This review shines a spotlight on recent amniotic fluid metabolomics studies and their methods as an interesting tool for the assessment of many conditions and the identification of biomarkers. Platforms in use, such as proton nuclear magnetic resonance ( 1 H NMR) and ultra-high-performance liquid chromatography (UHPLC), have different merits, and a combinatorial approach could be valuable. Metabolomics may also be used in the quest for habitual diet-induced metabolic signals in amniotic fluid. Finally, analysis of amniotic fluid can provide information on exposure to exogenous substances by detecting the exact levels of metabolites carried to the fetus and associated metabolic effects.

show abstract

“…Despite its tremendous burden on public health, spontaneous PTB (sPTB) remains poorly understood and relatively difficult to predict or prevent (Esplin et al, 2017 ; Honest et al, 2012 ). In fact, only recently has spontaneous PTB been considered as an obstetric ‘syndrome’, wherein one or more of a multitude of possible upstream pathways ultimately lead to a final common presentation (Souza et al, 2019a ). Some of the implicated etiological pathways involve inflammation, decidual hemorrhage, immunological factors, uterine stretch and endocrine derangement (Manuck et al, 2015 ; Behrman & Butler, 2007 ).…”

Section: Introductionmentioning

confidence: 99%

Metabolomic profiling of preterm birth in pregnant women living with HIV

Tobin,

Murphy,

et al. 2023

Metabolomics

View full text Add to dashboard Cite

Background Preterm birth is a leading cause of death in children under the age of five. The risk of preterm birth is increased by maternal HIV infection as well as by certain antiretroviral regimens, leading to a disproportionate burden on low- and medium-income settings where HIV is most prevalent. Despite decades of research, the mechanisms underlying spontaneous preterm birth, particularly in resource limited areas with high HIV infection rates, are still poorly understood and accurate prediction and therapeutic intervention remain elusive. Objectives Metabolomics was utilized to identify profiles of preterm birth among pregnant women living with HIV on two different antiretroviral therapy (ART) regimens. Methods This pilot study comprised 100 mother-infant dyads prior to antiretroviral initiation, on zidovudine monotherapy or on protease inhibitor-based antiretroviral therapy. Pregnancies that resulted in preterm births were matched 1:1 with controls by gestational age at time of sample collection. Maternal plasma and blood spots at 23–35 weeks gestation and infant dried blood spots at birth, were assayed using an untargeted metabolomics method. Linear regression and random forests classification models were used to identify shared and treatment-specific markers of preterm birth. Results Classification models for preterm birth achieved accuracies of 95.5%, 95.7%, and 80.7% in the untreated, zidovudine monotherapy, and protease inhibitor-based treatment groups, respectively. Urate, methionine sulfone, cortisone, and 17α-hydroxypregnanolone glucuronide were identified as shared markers of preterm birth. Other compounds including hippurate and N-acetyl-1-methylhistidine were found to be significantly altered in a treatment-specific context. Conclusion This study identified previously known as well as novel metabolomic features of preterm birth in pregnant women living with HIV. Validation of these models in a larger, independent cohort is necessary to ascertain whether they can be utilized to predict preterm birth during a stage of gestation that allows for therapeutic intervention or more effective resource allocation.

show abstract

Use of metabolomics for predicting spontaneous preterm birth in asymptomatic pregnant women: protocol for a systematic review and meta-analysis

Cited by 5 publications

References 28 publications

How could metabolomics change pediatric health?

How could metabolomics change pediatric health?

Utilizing Amniotic Fluid Metabolomics to Monitor Fetal Well-Being: A Narrative Review of the Literature

Metabolomic profiling of preterm birth in pregnant women living with HIV

Contact Info

Product

Resources

About